Chronic pulmonary hypertension (CPH) encompasses a heterogeneous group of disorders with the common feature of elevated pulmonary vascular resistance, accounting for approximately 42 million cases in 7MM in 2021. As per DelveInsight’s analysis, the 7MM prevalence is expected to increase at a considerable CAGR of 0.35% during the study period 2019–2032. The CPH prevalence is further divided into four main groups: Group 1, Group 2, Group 3, and Group 4. The most common group of CPH patients in Group 2 CPH (i.e., PH associated with left heart disease). It is estimated that approximately 3-4 million adults in the United States have Group 2 CPH. Furthermore, the World Heal...
